Mariner’s Metagenomi Therapeutics MGX Stock Holding History

Mariner’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,939	Closed	-$14.9K	–	3717
2025 Q1	$14.9K	Buy	+10,939	New	+$26.1K	﹤0.01%	3397

Other funds holding MGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVGI

Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mariner's MGX Position: Q2 2025 in Review

Mariner sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 10,939 shares — an estimated $14.9K sold.

Mariner first reported a position in MGX in Q1 2025 and held it in 1 quarter. The position peaked at $14.9K in Q1 2025. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

Mariner reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
Mariner sold 10,939 Metagenomi Therapeutics shares in Q2 2025, an estimated $14.9K.
Mariner first reported a position in Metagenomi Therapeutics in Q1 2025 and held it in 1 quarter.
Mariner's Metagenomi Therapeutics position peaked at $14.9K in Q1 2025.
69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Mariner's 13F filing for Q2 2025, filed 14 Aug 2025.